Last reviewed · How we verify
Bastel (EBASTINE)
At a glance
| Generic name | EBASTINE |
|---|---|
| Drug class | ebastine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Allergic rhinitis
- Chronic idiopathic urticaria
Common side effects
Key clinical trials
- Ebastine Versus Mebeverine in IBS Patients (PHASE3)
- Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome (PHASE2,PHASE3)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer (PHASE1,PHASE2)
- Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial (PHASE4)
- Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists (PHASE4)
- The Effect of Ebastine/Pseudoephedrine on Subacute Cough (NA)
- Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |